- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01767103
An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers
An Open-Label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox® in Subjects With Impaired Hepatic Function and Healthy Volunteers
Descripción general del estudio
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- University of Miami
-
Orlando, Florida, Estados Unidos, 32809
- Orlando Clinical Research Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Main Inclusion Criteria:
All subjects:
- Adult males or females, 18 - 75 years of age (inclusive);
- Body weight ≥ 50 kg;
- Body mass index (BMI) between 19 and 32 kg/mE2 (inclusive);
- Absolute neutrophil count (ANC) of >1.5x10E9/L ;
Healthy volunteers:
- Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical history, vital signs, physical examination);
- Matched to hepatically impaired subjects in the study by age (+/- 10 years), sex and weight (+/- 15% BMI).
Hepatically impaired subjects:
- Considered clinically stable in the opinion of the Investigator;
- Subjects with different degrees of impaired hepatic function as assessed by a Child-Pugh classification score: mild (Class A: 5-6 points) and moderate (Class B: 7-9 points) impaired hepatic function.
Main Exclusion Criteria:
- For subjects with hepatic impairment, fluctuating or rapidly deteriorating hepatic function as indicated by clinical and/or laboratory signs of hepatic impairment (e.g. advanced ascites, infection of ascites, fever, or active gastrointestinal bleeding).
- Evidence of liver impairment in healthy volunteers: hepatitis B and C; or aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, clotting factors, serum protein that is considered clinically significant by the Investigator;
- History or presence of significant clinically unstable respiratory, cardiovascular, pulmonary, hepatic (except for subjects assigned to one of the hepatically impaired groups), renal, hematologic, gastrointestinal, endocrine (except for subjects with hepatic impairment with clinically stable and treated diabetes, hypertension and thyroid disorders), immunologic, dermatologic, neurologic, or psychiatric disease;
- Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the PK of the investigational medicinal product (e.g. resections of the small or large intestine, febrile conditions, chronic diarrhea, chronic vomiting, clinically unstable endocrine disease, severe infections, acute inflammations, etc.);
- Received a pharmacological agent in another clinical trial within 28 days prior to the first dose of the study;
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Normal Hepatic Function (healthy volunteers)
Healthy volunteers with normal hepatic function received a single 33 mg/kg dose of Ferriprox®.
|
Otros nombres:
|
Experimental: Mild Hepatic Failure
Subjects with mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points received a single 33 mg/kg dose of Ferriprox®.
|
Otros nombres:
|
Experimental: Moderate Hepatic Failure
Subjects with moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points received a single 33 mg/kg dose of Ferriprox®.
|
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide
Periodo de tiempo: 24-hour interval
|
Cmax was assessed over a 24-hour interval for analyses of deferiprone and its 3-O-glucuronide metabolite in subjects with normal hepatic function, mild hepatic impairment, or moderate hepatic impairment.
Blood samples were obtained prior to dosing and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 9, 12, 16, and 24 hours post-dose.
|
24-hour interval
|
Tmax for Serum Deferiprone and Deferiprone 3-O-glucuronide
Periodo de tiempo: 24-hour interval
|
Tmax was assessed over a 24-hour interval for analyses of deferiprone and its 3-O-glucuronide metabolite in subjects with normal hepatic function, mild hepatic impairment, or moderate hepatic impairment.
Blood samples were obtained prior to dosing and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 9, 12, 16, and 24 hours post-dose.
|
24-hour interval
|
AUC0-∞ for Serum Deferiprone and Deferiprone 3-O-glucuronide
Periodo de tiempo: 24-hour interval
|
AUC (area under the curve) from zero to infinity was assessed over a 24-hour interval for analyses of deferiprone and its 3-O-glucuronide metabolite in subjects with normal hepatic function, mild hepatic impairment, or moderate hepatic impairment.
Blood samples were obtained prior to dosing and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 9, 12, 16, and 24 hours post-dose.
|
24-hour interval
|
T1/2 for Serum Deferiprone and Deferiprone 3-O-glucuronide
Periodo de tiempo: 24-hour interval
|
T1/2 was assessed over a 24-hour interval for analyses of deferiprone and its 3-O-glucuronide metabolite in subjects with normal hepatic function, mild hepatic impairment, or moderate hepatic impairment.
Blood samples were obtained prior to dosing and at 0.25, 0.50, 0.75, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 9, 12, 16, and 24 hours post-dose.
|
24-hour interval
|
CumAe for Urine Deferiprone and Deferiprone 3-O-glucuronide
Periodo de tiempo: 24-hour interval
|
Cumulative amount of deferiprone and deferiprone 3-O-glucuronide excreted in the urine. Urine samples were collected at the intervals of -2 to 0 hours pre-dose, and 0-2, 2-4, 4-8, 8-12 ,and 12- 24 hours post-dose. Note: For unknown reasons, the urine samples for one subject in the moderate hepatic failure group had low or zero volume and there were no measurable levels of deferiprone or its metabolite in any of the samples. Accordingly, the urine PK results were derived both with and without this subject's data, and are here presented without them (i.e., N=6 rather than 7). |
24-hour interval
|
Fe% for Urine Deferiprone and Deferiprone 3-O-glucuronide
Periodo de tiempo: 24-hour interval
|
Cumulative fraction of Ferriprox dose excreted in urine as deferiprone or deferiprone 3-O-glucuronide. Urine samples were collected at the intervals of -2 to 0 hours pre-dose, and 0-2, 2-4, 4-8, 8-12 ,and 12- 24 hours post-dose. Note: For unknown reasons, the urine samples for one subject in the moderate hepatic failure group had low or zero volume and there were no measurable levels of deferiprone or its metabolite in any of the samples. Accordingly, the urine PK results were derived both with and without this subject's data, and are here presented without them (i.e., N=6 rather than 7). |
24-hour interval
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Safety and Tolerability of Ferriprox in Subjects With or Without Hepatic Impairment.
Periodo de tiempo: Time of dosing until 48 hours post-dose
|
The number of participants who experienced adverse events following a single dose of Ferriprox, between the time of dosing and the follow-up visit (including any changes of clinical significance in physical examinations, vital signs, 12-lead ECG, and clinical laboratory tests).
|
Time of dosing until 48 hours post-dose
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Fernando Tricta, MD, ApoPharma
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- LA40-0412
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Ferriprox®
-
Imperial College LondonTerminadoEnfermedad de ParkinsonReino Unido
-
ApoPharmaTerminadoSobrecarga de hierro | Anemia drepanocítica | Otras AnemiasEstados Unidos, Reino Unido, Egipto, Canadá, Arabia Saudita
-
Ente Ospedaliero Ospedali GallieraActivo, no reclutandoSobrecarga de hierro | Enfermedad neurodegenerativaItalia
-
University Hospital, LilleApoPharmaTerminadoELA (Esclerosis Lateral Amiotrófica) | Sobrecarga de hierroFrancia
-
Children's Hospital of PhiladelphiaApoPharmaAprobado para la comercializaciónSobrecarga de hierroEstados Unidos
-
Chiesi Canada CorpYa no está disponibleNeurodegeneración asociada a pantotenato cinasa
-
Sheba Medical CenterHadassah Medical Organization; Kaplan Medical Center; Tel Aviv Medical Center; Ziv...TerminadoSíndrome mielodisplásico con lesiones de bajo grado | Sobrecarga de hierro debido a transfusiones repetidas de glóbulos rojosIsrael
-
ApoPharmaTerminado
-
Ain Shams UniversityDesconocido
-
ApoPharmaTerminado